Asset Advisors Investment Management LLC trimmed its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 55.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 48,495 shares of the healthcar

Confluence Wealth Services Inc. raised its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 25.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 44,422 shares of the healthcare product mak

Exchange Traded Concepts LLC increased its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 31.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 75,528 shares of the healthcare produc

Financial & Tax Architects LLC increased its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 25.3% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 80,248 shares of the healthcare product maker

Capital Investment Advisory Services LLC decreased its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 44.2% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 15,546 shares of the healthcare product maker

ABN Amro Investment Solutions raised its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 21.1% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 111,702 shares of the healthcare product maker

Alecta Tjanstepension Omsesidigt lifted its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 10.5% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,609,200 shares of the healthcare product maker

Abbott Laboratories anunció el jueves que acordó pagar alrededor de $670 millones para resolver parcialmente un litigio en curso que alega que su fórmula especial para bebés causó que los bebés prematuros sufrieran una condición intestinal incapacitante.

Abbott acordó un acuerdo de $670 millones por acusaciones de que sus fórmulas especiales para bebés prematuros causaron enterocolitis necrotizante. El acuerdo involucra a tres bufetes de abogados y unos 2.000 demandantes. Abbott niega responsabilidad pero busca resolver el litigio en curso vinculado a sus fórmulas y las de Mead Johnson.

Abbott Laboratories Reaches $670 Million Settlement in NEC Infant Formula Lawsuits

Abbott llegó a un acuerdo de 670 millones de dólares con tres bufetes de abogados para resolver reclamaciones de 2.000 personas relacionadas con presuntos daños causados ​​por sus fórmulas infantiles especiales. Anteriormente, un jurado había ordenado a Abbott pagar 495 millones de dólares por un caso relacionado. Este acuerdo aborda demandas similares centralizadas en varios estados.

Abbott pagará 670 millones de dólares para resolver las reclamaciones de Similac NEC vinculadas a 2.000 bebés; Quedan 1.700 trajes. Lea más aquí.